{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T08:40:34Z","timestamp":1778056834532,"version":"3.51.4"},"reference-count":20,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2017,2,26]],"date-time":"2017-02-26T00:00:00Z","timestamp":1488067200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Allergan plc, Dublin, Ireland"}],"content-domain":{"domain":["bjui-journals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["BJU International"],"published-print":{"date-parts":[[2017,6]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To examine whether response to first treatment with onabotulinumtoxinA is predictive of long\u2010term treatment outcome in patients with neurogenic detrusor overactivity (NDO).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods<\/jats:title>\n                    <jats:p>\n                      Patients with NDO who were enrolled in a 3\u2010year extension study (after a 52\u2010week phase III study) received onabotulinumtoxinA \u2018as needed\u2019, based on fulfilment of prespecified retreatment criteria. This\n                      <jats:italic>post hoc<\/jats:italic>\n                      analysis included patients who received only the 200\u2010U dose during the phase III and extension studies. Data on mean percent reduction from baseline in urinary incontinence (UI) episodes at week 6 after the first treatment were analysed, and the patients were stratified into three response groups: &lt;50% (group 1;\n                      <jats:italic>n<\/jats:italic>\n                      = 33), 50\u201374% (group 2;\n                      <jats:italic>n<\/jats:italic>\n                      = 23), and 75\u2013100% (group 3;\n                      <jats:italic>n<\/jats:italic>\n                      = 139). The following were assessed: change from baseline in mean percent UI reduction; proportions of patients who achieved \u226550% and 100% UI reduction after each subsequent treatment, and patients who achieved \u226550% UI reduction after all subsequent treatments; change from baseline in Incontinence Quality of Life (I\u2010QOL) total summary score; and the proportion of patients who achieved or exceeded the minimally important difference (MID; +11 points) in I\u2010QOL score. Adverse events (AEs) were also assessed.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The majority of the patients (83.1%; 162\/195) experienced a \u226550% UI reduction after onabotulinumtoxinA treatment 1. Baseline characteristics were largely similar across the groups. After treatment 1, the mean percent reduction in UI remained consistent in subsequent treatments 2\u20136 for patients in response group 2 (range: 64.5\u201383.5%) and group 3 (range: 79.4\u201388.0%), but increased for those in the low response group (range: 36.3\u201360.3%). After treatment 1, the proportion of patients who achieved \u226550% reduction in UI episodes was consistent with subsequent treatments 2\u20136 in group 2 (range: 75.0\u2013100%) and group 3 (range: 87.3\u201397.1%), but increased in the low response group (range: 48.3\u201372.7%). Even among those who achieved a low response after treatment 1, 37.9% of patients achieved \u226550% UI reduction in all subsequent treatments. Improvements in I\u2010QOL scores in groups 2 and 3 were consistently 2\u20133 times the MID. In the low response group, at least 50% of the patients achieved or exceeded the MID with treatments 2\u20136. AEs were similar across all response groups and consistent across repeated treatments.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Patients with NDO with a \u226550% UI reduction after their first onabotulinumtoxinA treatment continued to experience consistent improvements in UI and quality of life with subsequent treatments over the duration of 4 years. A &lt;50% UI reduction after first treatment did not necessarily predict low response with subsequent treatments. Thus, these results underscore the importance of attempting at least a second treatment with onabotulinumtoxinA before deeming patients unsuitable for onabotulinumtoxinA therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/bju.13795","type":"journal-article","created":{"date-parts":[[2017,1,31]],"date-time":"2017-01-31T02:24:05Z","timestamp":1485829445000},"page":"926-932","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Positive outcomes with first onabotulinumtoxinA treatment persist in the long term with repeat treatments in patients with neurogenic detrusor overactivity"],"prefix":"10.1111","volume":"119","author":[{"given":"Pierre","family":"Denys","sequence":"first","affiliation":[{"name":"H\u00f4pital Raymond Poincar\u00e9 Garches France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roger","family":"Dmochowski","sequence":"additional","affiliation":[{"name":"Vanderbilt University Medical Center Nashville TN USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip","family":"Aliotta","sequence":"additional","affiliation":[{"name":"Western New York Urology Associates, LLC Cheektowaga NY USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Castro\u2010Diaz","sequence":"additional","affiliation":[{"name":"Hospital Universitario de Canarias Universidad de La Laguna Santa Cruz de Tenerife Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bertil","family":"Blok","sequence":"additional","affiliation":[{"name":"Erasmus Medical Centre Rotterdam The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen","family":"Ethans","sequence":"additional","affiliation":[{"name":"University of Manitoba Winnipeg MB Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tamer","family":"Aboushwareb","sequence":"additional","affiliation":[{"name":"Allergan plc Irvine CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Magyar","sequence":"additional","affiliation":[{"name":"Allergan plc Bridgewater NJ USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Kennelly","sequence":"additional","affiliation":[{"name":"Carolinas Rehabilitation Charlotte NC USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2017,2,26]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrn2401"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/nau.21003"},{"key":"e_1_2_7_4_1","unstructured":"BOTOX (onabotulinumtoxinA) [package insert].Dublin Ireland:Allergan plc;2015."},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2011.07.002"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2012.01.125"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-013-0054-z"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/nau.22934"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-11-13"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.2147\/BTT.S65603"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(98)00454-3"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.apmr.2007.02.009"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2011.07.001"},{"key":"e_1_2_7_14_1","unstructured":"Urinary incontinence in neurological disease: assessment and management.www.nice.org.uk\/guidance\/cg148. 8 August 2012."},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2015.07.071"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/ijcp.12360"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2014.09.001"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/nau.22376"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/sc.2013.19"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/816274"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.5489\/cuaj.3098"}],"container-title":["BJU International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbju.13795","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bju.13795","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T17:07:35Z","timestamp":1761757655000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/10.1111\/bju.13795"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,26]]},"references-count":20,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["10.1111\/bju.13795"],"URL":"https:\/\/doi.org\/10.1111\/bju.13795","archive":["Portico"],"relation":{},"ISSN":["1464-4096","1464-410X"],"issn-type":[{"value":"1464-4096","type":"print"},{"value":"1464-410X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2,26]]},"assertion":[{"value":"2017-02-26","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}